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Implication for health policy/practice/research/medical education:
It is imperative to highlight the early monitoring of patients with AKI and carefully control kidney function during severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
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Coronavirus disease 2019 (COVID-19) is now a pandemic and its death toll is rocketing up. Patients 
with acute kidney injury (AKI) and chronic kidney disease (CKD) are at high risk of developing 
COVID-19 complications and COVID-19 infection can also lead to renal dysfunction. Considering 
the importance of kidney function in COVID-19 patients, the present review is aimed to dig into 
the available evidence about kidney and COVID-19. We summarize the mechanisms underlying 
the renal injury in COVID-19 patients, and treatment strategies in dialysis and kidney transplant 
patients. We conclude, it is imperative to highlight the early monitoring of patients with AKI and 
carefully control kidney function during severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) infection.
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Introduction
Coronaviridae family of viruses can cause diseases in 
mammals and birds, and possess enveloped particles 
containing single-stranded and positive-sense RNA. 
Coronavirus infection can lead to the diseases ranging 
from a mild condition such as common cold to severe 
diseases including severe acute respiratory syndrome 
coronavirus (SARS-CoV), Middle East respiratory 
syndrome coronavirus (MERS-CoV) and severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), a 
novel coronavirus emerged in Wuhan city, China (1, 
2). Coronavirus disease 2019 (COVID-19) pandemic 
continues to expand quickly all over the world. The 
virus is transmitted through the same mechanisms 
as of influenza virus, from person to person through 
sneezing and coughing or contact with the secretion of 
infected persons. COVID-19 disease is more severe in 
the elderly, and persons with other chronic diseases such 
as chronic respiratory disease, diabetes, cardiovascular 
disease, hypertension, and renal injury (3). The most 
common symptom and signs of COVID-19 illness 
include fatigue, fever, and dry cough, as well as sputum 
production, headache, hemoptysis, diarrhea, dyspnea, 
and lymphopenia (4). Numerous trials are underway to 
identify effective drug regimens for COVID-19. The 
development of preventative vaccine or the discovery of 
novel drug candidates are in early phases. However, some 
broad-spectrum drugs are in use to mitigate the infection 
in patients with COVID-19 (5). A minority of patients 
develop multi-organ failure which aggravates COVID 19 
mortality rate. It is estimated that organ dysfunction in 
patients with COVID-19 occurs in about 33%, of which 
3-7% are related to acute kidney injury (AKI) (6,7). Old 
data from SARS and MERS-CoV infections have reported 
AKI development in 5%-15% cases (8). COVID-19 
progression leads to renal dysfunction or renal injury as 
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well as respiratory system injury (9). Given the importance 
of kidney function in COVID-19 patients, the present 
review is allocated to focus on the available evidence of 
renal disease and COVID-19.
COVID-19 and renal impairment 
Patients with renal injury are at high risk of developing 
COVID-19 and AKI is an important risk factor for 
COVID-19 patients (8). Furthermore, renal impairment is 
one of the complications of SARS-CoV-2 infection. A large 
prospective study demonstrated that kidney impairment 
is more prevalent among hospitalized COVID-19 patients 
and is also associated with increased in-hospital death. 
Frequently COVID-19 patients, at the time of admission 
have proteinuria (44%), hematuria (26.9%), increased 
blood urea nitrogen (14.1%), and increased plasma 
creatinine (15.5%) (10). During this study, 3.2% of patients 
developed AKI in the early days. This study emphasized the 
need for early interventions such as proper hemodynamic 
support and abstinence of nephrotoxic drugs as well as 
performing urine analysis in patients with COVID-19 
to prevent kidney injury (10). In contrast to this survey, 
a study found that AKI is rare in COVID-19 and SARS-
CoV-2 infection does not lead to renal disturbance 
or exacerbation of chronic kidney disease (CKD) in 
COVID-19 patients (11). Hong et al, which evaluated 
the incidence of early renal injury in COVID-19 patients 
demonstrated the presence of abnormalities in levels of 
estimated glomerular filtration rate (66.7%), creatinine 
clearance (41.7%), and increased microalbuminuria 
(41.7%), without significant abnormalities in blood urea 
nitrogen and plasma creatinine. They sound that the 
measurement of urine microalbumin, α1-microglobulin, 
urine immunoglobulin-G, and urine transferrin are more 
helpful in the diagnosis of early renal injury in COVID-19 
patients (12). 
Available data suggest that SARS-CoV-2 infection can 
have a direct cytotoxic effect on renal tubules and cause 
acute renal failure. Retrospective analysis of 85 patients 
with COVID-19 demonstrated that 27.06% of patients 
developed acute renal failure, especially in elder patients. 
Furthermore, kidney tissue examinations of postmortem 
specimens confirmed lymphocyte infiltration, severe acute 
tubular necrosis, and accumulation of viral nucleocapsid 
protein antigen in kidney tubules (13). The presence of 
SARS-CoV-2 virus particles in urine of COVID-19 patients 
might be due to penetration of viral particles through 
glomerular barrier (14). It is also reported that 51.67 % 
of patients affected by novel coronavirus pneumonia had 
proteinuria since the severity of pneumonia was directly 
associated with levels of urine protein (15). 
COVID‐19 and kidney transplant recipients
Infections are a leading cause of morbidity and mortality 
in renal allograft recipients throughout the post-
transplant course. Viruses are the most common causes 
of opportunistic infection after transplantation. Different 
factors that promote active invasive viral infection 
after organ transplantation include inflammation, graft 
rejection, tissue injury, and immune suppression (16). 
Previous studies have reported the SARS-CoV and 
MERS-CoV infections in transplant recipients (17,18). 
In the current pandemic, SARS-CoV-2 infection has 
been reported in kidney transplant patients from China 
and Spain (19,20). Reduction of immunosuppressive 
agents, along with low dose methylprednisolone-based 
regimes could improve COVID-19 pneumonia in a renal 
transplant recipient with long-term immunosuppressive 
therapy (21). Although there is not much data available 
on the incidence of COVID-19 in transplant recipients, 
it is recommended to follow preventive modalities and 
guidelines to prevent the spread of the disease (22, 23).
COVID-19 and dialysis patients 
COVID-19 is a serious threat for dialysis patients in 
hemodialysis (HD) centers. Dialysis patients are more 
vulnerable to SARS-CoV-2 infection than the general 
people, due to thrice-weekly outside exposure for HD, 
older age and underlying chronic conditions (24). The 
study by Ma et al on 230 HD patients and 33 staff members 
of 61 HD centers in Wuhan confirmed the presence of 
COVID-19 infection in 37 of HD patients and 4 staff 
members. Among 37 COVID-19 infected HD patients, 
death occurred in 6 cases that was presumably due to 
cardiovascular, cerebrovascular diseases, and hyperkalemia 
but not exclusively due to COVID-19 pneumonia (25). 
Despite higher level of inflammatory cytokines in HD 
patients, compared to controls, lower serum level of 
inflammatory cytokines in COVID-19 patients on HD 
compared to other COVID-19 was detected. Additionally, 
HD patients with COVID-19 showed lower frequency 
of lymphocytes in peripheral blood mononuclear cells 
than other COVID-19 patients (25). Currently, the risk 
of SARS-CoV-2 infection transmission to HD patients 
and their families, medical staff, workers, and others 
is significantly high in HD centers (8). Therefore, the 
Taiwan society of nephrology (26), the Chinese society 
of nephrology (27), and the Centers for Disease Control 
and Prevention (28) have published guidelines for HD 
centers for the COVID-19 pandemic. As the prevention, 
protection, screening, isolation, and distribution are 
basic principles in the reduction and containment of the 
COVID-19 in HD centers, the management of dialysis 
patients with COVID-19 must be conducted based on 
standard protocols (29).
Mechanisms of renal injury in COVID-19
Recent studies revealed that renal dysfunction during 
SARS-CoV-2 infection is closely related to death in 
severe cases of COVID-19 patients. Although the exact 
mechanism is not fully clarified, it is possible that the 
expression pattern of angiotensin-converting enzyme 2 
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(ACE2) can be associated with cellular susceptibility of 
SARS-CoV infection (30). SARS-CoV-2 enters into cells 
using the ACE2 receptor and cellular transmembrane 
serine proteases (TMPRSSs) as a co-receptor. ACE2, as a 
membrane-bound aminopeptidase, is highly expressed in 
the lungs, heart, intestine, kidneys and plays a fundamental 
role in the immune and cardiovascular systems and renal 
function (31,32). The penetration of SARS-CoV-2 virus 
into the renal tubular cells, by binding to ACE2, induces 
cytotoxicity and renal function impairment (33). Single-
cell RNA sequencing analysis of kidney cells has revealed 
that ACE2 is expressed along with TMPRSSs in proximal 
straight tubule cells and podocytes, indicating that the 
kidney cells are exposed to SARS-CoV-2 infection. 
TMPRSSs activate the spike protein of the virus surface 
for membrane fusion into host cells (34).
The cytokine storm syndrome involved in pathogenesis 
of the acute respiratory distress syndrome (ARDS) and 
various organs failure during SARS-CoV infection, seems 
to be related to enormous inflammatory reaction. The viral 
replication in targeted organs, including kidneys, induces 
systematic viral sepsis and systematic inflammatory 
responses, and subsequently cell damage in multiple 
organs (35). Additionally, SARS-CoV-2 infection activates 
cytokine cascade through releasing pro-inflammatory 
cytokines ( IL-4, IL-10, IL-1b, IFN-c, IP-10 and MCP-1) 
and chemokines (CCL2, CCL3, CCL5, CXCL1, CXCL8 
and CXCL9), thereby resulting in the death of patients, as 
observed in SARS-CoV and MERS-CoV infections (36, 
37). In addition, renal failure in COVID-19 patients may 
occur due to rhabdomyolysis, hypoxemia, dehydration, 
presence of underlying diseases, and improper 
consumption of non-steroidal anti-inflammatory drugs 
(Figure 1) (38,39).
ACE2-based therapeutic strategies
Renal disorders, which initially appeared as mild 
abnormalities, may later be diagnosed as severe AKI in a 
significant proportion of patients. Since the progression 
of AKI in COVID-19 patients is an important prognostic 
factor, patients may be treated with some more directive 
interventions (9). Findings have suggested that the kidney 
cells are one of the target organs of COVID-19 virus, due 
to the expression of ACE2 and TMPRSS2. Agents targeting 
virus spike protein, protease TMPRSS2, and ACE2 
receptor are to emerging as potential clinical strategies for 
prevention and therapy (40). In vitro studies using Vero-E6 
monkey kidney cell line, demonstrated that SARS-CoV 
replication is blocked by a soluble form of ACE2 (41). 
Hence, it has been assumed that the soluble recombinant 
human ACE2 protein may be a therapeutic option to 
combat or limit SARS-CoV-2 infection progression (42). 
In support of this hypothesis, a previous study on an 
animal model has illustrated the beneficial effect of small 
ACE2 variants in the improvement of AKI by regulating 
kidney renin-angiotensin system activity (43). Further 
studies in engineered human organoids, including kidney 
organoids, revealed that the human recombinant soluble 
ACE2 (hrsACE2) can block the growth of SARS-CoV-2 in 
the early stages of infection (44). In addition, a clinically 
proven TMPRSS2 inhibitor, named camostat mesylate, 
prevents the cell entry of SARS-CoV-2 and might 
constitute a treatment option for COVID-19 (45). 
Conclusion
COVID-19 virus attacks the cells expressing ACE2 and 
induces multiple organ injury. Kidney injury caused 
by COVID-19 increases mortality and morbidity 
substantially. Close monitoring of patients renal function, 
avoidance of nephrotoxins, and minimizing studies and 
interventions that can potentially harm kidneys, are 
especially important. In the absence of proven established 
drug regimens, aggressive supportive measures are needed 
in caring for patients with COVID 19 multiorgan failure. 
Still much further studies are warranted to reveal more 
and newer information on our uncharted understanding 
of this disease.
Figure 1. COVID-19 -induced acute kidney injury.
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